C

Caladrius Biosciences Inc
LSE:0HS8

Watchlist Manager
Caladrius Biosciences Inc
LSE:0HS8
Watchlist
Price: 4.57 USD 13.4% Market Closed
Market Cap: $88.6m

Operating Margin

-1 876.4%
Current
Improving
by 184.9%
vs 3-y average of -2 061.4%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 876.4%
=
Operating Income
$-20.1m
/
Revenue
$1.1m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 876.4%
=
Operating Income
$-20.1m
/
Revenue
$1.1m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Caladrius Biosciences Inc
LSE:0HS8
78.1m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.3B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.4B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 14 112 companies
5th percentile
-1 876.4%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Caladrius Biosciences Inc
Glance View

Market Cap
88.6m USD
Industry
Biotechnology

Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 27 full-time employees. The firm is developing therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company’s product candidates include CLBS16, CLBS12 and CLBS201. The CLBS16 (XOWNA) is an experimental regenerative medicine that is being studied in a Phase IIb study (the FREEDOM trial) in the United States for the treatment of coronary microvascular dysfunction. The CLBS12 (HONEDRA) is an experimental regenerative medicine being studied in Japan for the prevention of serious adverse consequences of critical limb ischemia. The CLBS201 is an experimental regenerative medicine designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease.

0HS8 Intrinsic Value
2.08 USD
Overvaluation 55%
Intrinsic Value
Price
C
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-1 876.4%
=
Operating Income
$-20.1m
/
Revenue
$1.1m
What is Caladrius Biosciences Inc's current Operating Margin?

The current Operating Margin for Caladrius Biosciences Inc is -1 876.4%, which is above its 3-year median of -2 061.4%.

How has Operating Margin changed over time?

Over the last 9 months, Caladrius Biosciences Inc’s Operating Margin has increased from -2 240.9% to -1 876.4%. During this period, it reached a low of -2 240.9% on Dec 31, 2024 and a high of -1 876.4% on Oct 30, 2025.

Back to Top